At a glance
ClinicalIndex Comparison RecordN/ACompleted· 160 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Observational Study to Evaluate NeoRecormon Treatment in Anemic Patients Suffering From Non-myeloid Malignancy Receiving Chemotherapy
In Brief
An observational study for Anemia. Completed, enrolled 160 participants across 6 sites.
Detailed Summary
This observational, prospective, multicenter study will evaluate the treatment response rate and the safety of NeoRecormon (epoetin beta) in anemic patients with non-myeloid malignancy. In addition to NeoRecormon, patients receive chemotherapy for their malignancy. Data will be collected for 16 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesHungary
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
Primary CompletionMar 2012
First PostedOct 2012
TodayJul 2026
First PostedOct 30, 2012
Enrollment StartAug 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.7 years ago